Tekmira Pharmaceuticals expects to receive $11.2 million during the next three years from partner Alnylam Pharmaceuticals for process development and manufacturing services. This commitment is part of the company’s manufacturing pact with Alnylam for the development of RNAi therapeutics through Phase II using Tekmira’s SNALP technology, including Alnylam’s clinical candidate ALN-VSP. The manufacturing and development funding is in addition to ongoing research activities between...